pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
SARCLISA for Patients aged 18-65 years old w…
Phase 3 · small molecule · Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.
SARCLISA for Patients aged 18-65 years old w… for Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL. is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.
- Status
- active
- Trials
- 1